Alizé Pharma 3 has raised €67m ($75m) to take two endocrinology and metabolism drugs into human testing and through to the delivery of mid-phase data.
Alizé Pharma 3 Raises €67m To Build ‘Fully Fledged’ Biotech
The Series A financing positions Alizé to take a rival to Shire’s Natpara through to clinical proof of concept over the next few years.
